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INTRODUCTION
188Re (Rhenium) is a short-lived beta emitting radionuclide
(physical half-life=17 hr, Emax=2.11 MeV). It has an average
beta particle penetration of 3.3 mm (maximum=10.8), pro-
viding a tightly circumscribed region of high-energy depo-
sition with little damage to the adjacent cells and organs. In
addition, 188Re is easily obtained from an in-house 188W/188Re
generator similar to the current 99Mo/99mTc generator, which
makes it convenient for clinical use (1-4). These characteristics
make this radionuclide a promising candidate as a therapeu-
tic agent.
Polyethylenimine (PEI) is a cationic polymer that has re-
cently appeared as a possible alternative to viral and liposomal
routes for gene delivery (5). PEI has been studied as a chelat-
ing agent to remove heavy metal ions (6, 7). Because PEI con-
tains primary, secondary, and tertiary amines, PEI derivatives
can be chelated with a radionuclide such as 188Re. PEI can also
be coupled to ligands such as galactose or transferrin (Tf) for
the purpose of targeting specific organ or tumor cells (8-12).
Therefore, ligand binding PEI derivatives labeled with 188Re
may be used as a novel radiopharmaceutical in targeting ther-
apy for tumor treatment.
Use of Tf conjugates for site-specific drug delivery and gene
delivery to tumor cells has been studied via intravenous injec-
tion (13, 14). Xu et al. reported that an intratumoral injection
using the Tf-liposome system showed a higher number of
transfected tumor cells in vivo when compared with transfec-
tion by liposome alone (15). These results indicate that irre-
spective of the route of injection, Tf conjugates specifically
bind to Tf receptors (Tf-R) present in the tumor cell mem-
brane. These complexes then enter the cells by receptor-medi-
ated endocytosis. This study investigated whether intratumoral
injections of 188Re labeled Tf-PEI conjugates exert the full
effect of radionuclide therapy against the tumor cells.
MATERIALS AND METHODS
Synthesis of HYNIC-PEI-Tf conjugates
Tf-PEI (branched PEI, 25 kDa) conjugates were synthesized
as described by Kircheis and coworkers (16). Branched PEI
was purchased from Aldrich (WI, U.S.A.). Briefly, human
apo-transferrin in 30 mM sodium acetate buffer (pH 5.0) was
subjected to gel filtration on a Sephadex G-25 superfine col-
umn (Pharmacia, Uppsala, Sweden). The resulting solution
was cooled to 0℃ and sodium periodate (in 30 mM pH 5
sodium acetate buffer) were added. The mixture was kept in
an ice bath in the dark for 90 min and promptly added to
Eun-Mi Kim*, Hwan-Jeong Jeong*
,� ,
Young-Jun Heo
�, Hyung-Bae Moon
� ,� ,
Hee-Seung Bom
�, Chang-Guhn Kim*
*Department of Nuclear Medicine; 
� Wonkwang 
University Institute of Medical Science; 
� Department of
Pathology, Wonkwang University School of Medicine,
Iksan; 
�Department of Nuclear Medicine, Chonnam
National University School of Medicine, Gwangju,
Korea
Address for correspondence
Hwan-Jeong Jeong, M.D.
Department of Nuclear Medicine, Wonkwang University
Hospital, 344-2 Sinyong-dong, Iksan 570-711, Korea
Tel : +82.63-850-1367, Fax : +82.63-852-1310
E-mail : jayjeong@wonkwang.ac.kr
647
J Korean Med Sci 2004; 19: 647-51
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Intratumoral Injection of 
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188Re (Rhenium) is easily obtained from an in-house 
188W/
188Re generator that is similar
to the current 
99Mo/
99mTc generator, making it very convenient for clinical use. This
characteristic makes this radionuclide a promising candidate as a therapeutic agent.
Polyethylenimine (PEI) is a cationic polymer and has been used as a gene delivery
vector. Positively charged materials interact with cellular blood components, vascular
endothelium, and plasma proteins. In this study, the authors investigated whether
intratumoral injection of 
188Re labeled transferrin (Tf)-PEI conjugates exert the effect
of radionuclide therapy against the tumor cells. When the diameters of the Ramos
lymphoma (human Burkitt’s lymphoma) xenografted tumors reached approximately
1 cm, 3 kinds of 
188Re bound compounds (HYNIC-PEI-Tf, HYNIC-PEI, 
188Re perrhen-
ate) were injected directly into the tumors. There were increases in the retention of
188Re inside the tumor when PEI was incorporated with 
188Re compared to the use of
free 
188Re. The 
188Re HYNIC-Tf-PEI showed the most retention inside the tumor (reten-
tion rate=approximately 97%). H&E stain of isolated tumor tissues showed that 
188Re
labeled HYNIC-PEI-Tf caused extensive tumor necrosis. These results support 
188Re
HYNIC-PEI-Tf as being a useful radiopharmaceutical agent to treat tumors when
delievered by intratumoral injection.
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PEI solution and mixed at room temperature. After 30 min,
four portions of sodium cyanoborohydride were added at 1
hr intervals. After 18 hr, 3 M sodium chloride was added.
The reaction mixture was loaded on a cation-exchange col-
umn, Macro-Prep high S HR 10/10 (Bio-Rad, Hercules, CA,
U.S.A.) and was fractionated with a salt gradient from 0.5
M to 3.0 M sodium chloride in 20 mM HEPES (pH 7.3). A 3
molar excess of dissolved succinimidyl 6-hydrazino nicotinate
hydrochloride (HYNIC) (5 mol% of PEI amino group) in
30 mM dimethyl-formamide (DMF) was added dropwise to a
stirred solution of Tf-PEI conjugates. The solution was stirred
gently for 24 hr at 4℃protected from light. This was follow-
ed by dialysis against HBS (pH 7.3, 150 mM sodium chlo-
ride, 20 mM HEPES) at 4℃ (six buffer changes for 72 hr).
The iron incorporation was performed by addition of 1.25  L
10 mM iron (III) citrate buffer per mg transferrin content. The
conjugates were divided into convenient small aliquots and
kept at -20℃.
Labeling with 188Re 
188Re-perrhenate was obtained in 20 mL of normal saline
from 188W/188Re generator (Shanghai Ke Xing Pharmaceu-
ticals, Shanghai, China). The labeling process was carried out
in the presence of stannous chloride dehydrate. 188Re sodium
perrhenate eluate (370 MBq) in 0.9% normal saline was mix-
ed in a vial with 10 mg of ascorbic acid, 40 mg of SnCl2 (Si-
gma, U.S.A.), and 500  L of HYNIC-PEI-Tf (1  g/ L) or
HYNIC-PEI. Then, the vial was reacted at 37℃for 1 hr. The
labeling yield was determined by ITLC-SG (Gelman Science,
Ann Arbor, MI, U.S.A.) using acetone as the mobile phase.
In vivo animal model
To generate tumors, three 5- to 6-week-old female BALB/c
nude mice (Orient Co. Ltd., Seoul, Korea) were injected sub-
cutaneously in the left thigh with Ramos cells (ATCC CRL
1596, human Burkitt’s lymphoma, 5×106 cells/100 L).
Tumor size was measured using a vernier caliper across its
longest and after the diameters were reached about 1 to 1.5
cm, 3 kinds of 188Re labeled compounds (300  Ci of HYNIC-
PEI-Tf, HYNIC-PEI, and free 188Re) were injected directly
three times into the tumors, respectively. 
Image acquisition
Static images were acquired with a gamma camera (Vertex,
ADAC, Milpitas, CA, U.S.A.) equipped with a low energy,
pin-hole collimator, and with a 40% window centered over
the 155-keV photopeak. Gamma images were achieved from
10 min to 12 hr after injection to certifying intratumoral
retention of 188Re HYNIC-PEI-Tf (11.1 MBq/mouse) and
188Re HYNIC-PEI in comparison with that applied with
same dose of 188Re perrhenate.
Hematoxylin & eosin staining
Histologic evaluation with H&E staining was performed
2 days after injection. The frozen sections were washed with
tap water for 5 min, immersed in hematoxylin for 2 min and
checked for complete staining in tap water. Eosin staining
was carried out for 3 min. Sections were dehydrated through
a graded series of alcohol (70 to 100% ethanol, 3 min each),
cleared in xylene, cover-slipped and observed with a light
microscope.
Image analysis and dosimetry
Region of interest (ROI) were drawn manually on 10 min
image around the tumor and whole body. ROIs of the same
size and shape were applied to 2 hr and 12 hr images. Reten-
tion rates of 3 radiotracers were calculated. A half-life for 188Re
HYNIC-PEI-Tf was also calculated in the form of effective
half-life and the residence time was defined as half-life/ln 2.
Tumor self-radiation S-value of 188Re HYNIC-PEI-Tf was
obtained using the Nodule Module in MIRDOSE3.1 soft-
ware (Oak Ridge Associated University) (17). From the cal-
culated S-values and residence time in the mouse model, the
dose of 188Re HYNIC-PEI-Tf to obtain 100 Gy of tumor irra-
diation was calculated.
Reverse transcription-polymerase chain reaction
Total RNA isolated from Ramos cells with Trizol reagent
(Invitrogen, U.S.A.) was used for RT-PCR. First-strand cDNA
synthesis was performed at 42℃ for 50 min, followed by 70
℃ for 15 min using Superscript II reverse transcriptase and
oligo (dT)10 as the primer. The cDNA was amplified using
the following primers: Tf-R F 5′ CTCACTTTAGACAAT-
GCTGC 3′ ; Tf-R R 5′ CTCATGACACGATCATTGAG 3′ .
A pair of primers specific to  -actin (F 5′ -TGACGGGGT-
CACCCACACTGTGCCCATC TA-3′ ; R 5′ -CTAGAAG-
CATTTGCGGTGGACGATGCAGGG-3′ ) was used as a
control. PCR was performed in a DNA thermal cycler using
94℃ melting, 45℃ annealing, and 72℃ extension temper-
atures for 33 cycles. The PCR products were loaded on agarose
gel (1%) containing ethidiume bromide and electrophoresis
was performed at 100 V for 20 min.
RESULTS
The labeled 188Re HYNIC-PEI-Tf or HYNIC-PEI remain-
ed localized at the origin of injection and radiochemical puri-
ties of these labeled compounds at 15 min and 1 hr were 97%
and 80%, respectively.
Fig. 1A, B showed that when PEI was incorporated with
188Re, the retention of 188Re inside the tumor was increased
compared with free 188Re. The 188Re HYNIC-PEI-Tf mostlyIntratumoral Injection of 
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remained in the tumor and showed a higher retention rate
than 188Re HYNIC-PEI (approximately 97% vs. 85%). 188Re
HYNIC-PEI released from the tumor accumulated in the
liver and lungs. Fig. 1C showed that free 188Re escaped from
the tumor over time and that there was no remaining 188Re
12 hr after injection. The 188Re released accumulated in the
stomach, thyroid, and bladder in much the same way that
99mTc pertechnetate did.
Effective half-life of 188Re HYNIC-PEI-Tf was assumed to
be same to the physical half-life. The caculated residence time
of this conjugate was 24.5 hr. The nodular self-dose S-value
was estimated as 0.343 mGy/MBq ∙ h. using MIRDOSE3.1.
The radioactivity required for a target irradiation dose of 100
Gy for 0.97 to 1.23 cm tumor was calculated 6.4 to 11.9 MBq
for 188Re HYNIC-PEI-Tf from this S-value.
Representative hematoxylin and eosin-stained sections of
the isolated tumors injected with 188Re HYNIC-PEI-Tf and
188Re perrhenate were shown in Fig. 2. In the tumor injected
with 188Re HYNIC-PEI-Tf, histological changes were found
in contrast with 188Re perrhenate. 188Re HYNIC-PEI-Tf made
extensive central necrosis inside the tumor and remained the
small portion of viable tumor tissue around the tumor mass.
The result of RT-PCR represented the Ramos Burkitt’s
lymphoma cells had Tf-R mRNA and the possibility of ex-
pression of Tf-R protein on the cell membrane (Fig. 3).
DISCUSSION
Our preliminary results show that intratumoral injection
with 188Re HYNIC-PEI-Tf caused extensive necrosis in the
xenografted tumor without a significant leakage of radioac-
tive compound. Although PEI could chelate with 99mTc or
188Re because of the secondary or tertiary amine groups in
this polymer, in this study HYNIC was introduced as a bi-
conjugate for higher and safer labeling.
188Re has not only strong potential for therapeutic use but
also excellent imaging characteristics because of its  energy
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Fig. 1. Gamma images of Ramos lymphoma xenografted nude
mice 10 min, 2 hr, and 12 hr after intratumoral injection. (A) Of three
kinds of 
188Re conjugates, 
188Re HYNIC-PEI-Tf showed the highest
retention rate inside the tumor and relatively no leakage from the
tumor when radionuclides were injected intratumorally. (B) With
time, 
188Re HYNIC-PEI escaped from the tumor with some extent
(approximately 15%) and accumulated into the lung and liver.
(A) 
188Re HYNIC-PEI-Tf injected mouse, (B) 
188Re HYNIC-PEI inject-
ed mouse, (C) 
188Re perrhenate injected mouse.
L, liver; T, tumor; ch, chest; th, thyroid; S, stomach; B, bladder.
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Fig. 2. Hematoxylin-eosin staining obtained 48 hr after intratumoral
injection. (A, B) Histological findings (H&E, original magnification
×10, ×200) demonstrate that wide central necrosis with peripher-
al viable cells is shown when 
188Re HYNIC-PEI-Tf is injected, but
(C, D, H&E ×10, ×200) no significant necrosis when 
188Re perrhe-
nate injected.
T, tumor; N, necrosis; M, muscle.
Fig. 3. The result of
RT-PCR for Tf-recep-
tor in Ramos lympho-
ma cells. The result
demonstrates that Ra-
mos lymphoma cells
had mRNA of human
Tf-receptor. Lane 1:  -
actin as control, Lane
2: Tf-R. MK: Molecu-
lar size marker.
MK Tf-R
12
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(2.1 MeV), its short physical half-life (17 hr) and its 155 keV
-ray emission; often used for dosimetric and imaging pur-
poses. Therefore many researchers have used 188Re in a vari-
ety of fields such as intravascular radiation, radioimmunother-
apy using monoclonal antibodies, and metastatic bone lesions
(2-4). Radiotherapy using 188Re needs novel therapeutic strate-
gies, which can facilitate an increase in the intratumoral uptake
or a retention and reduction in its systemic levels. Radiother-
apy with intratumorally-injected radiopharmaceuticals is a
promising approach to some kinds of tumor such as head and
neck cancers because it offers the potential to localize the radi-
ation inside the tumor. Because potential leakage of therapeu-
tic radionuclide causes serious problems in the site of accu-
mulation, there is a need to minimize leakage of the inject-
ed compound. Intratumoral injection of 188Re HYNIC-PEI-
Tf resulted in the highest retention in the tumor mass indi-
cating this approach had strong potential for the treatment
of solid tumors. 
PEI is a cationic polymer and has been used as a gene deliv-
ery vector. Positively charged materials interact with cellular
blood components, vascular endothelium, and plasma pro-
teins when they are injected systemically (18, 19). In this
study, 188Re HYNIC-PEI leaked out from injected site showed
the liver and lung activity, this might be explained that posi-
tive surface charge of PEI led to interactions with lung and
hepatic endothelium. Until now, there have been few reports
about intratumoral injection using 188Re labeled cationic poly-
mer. Therefore, despite of incomplete and preliminary data,
our result is thought to be introduced the new, useful com-
pound to the field of radionulide therapy.
High retention of 188Re HYNIC-PEI in the tumor demon-
strates that the intratumoral injections of positively charged
radioactive conjugates bind to tumor cells adjacent to the
injection sites. Based on the fact that Tf-PEI derivatives/DNA
complexes have been known to deliver the gene efficiently
through the Tf-Tf receptor system, in the intratumoral app-
roach of 188Re HYNIC-PEI-Tf, Tf-Tf receptor mediated tu-
moral uptake is thought to play an additional role for higher
retention of radiocompound in the tumor than that of 188Re
HYNIC-PEI. We certified the existence of Tf-receptor mRNA
through RT-PCR method in the Ramos lymphoma cell line.
Another role of Tf conjugate as a ligand may be that Tf en-
larged the size of 188Re labeled polymer because the molecu-
lar weight of Tf is relatively heavy, about 80 kDa.
As shown in Fig. 1, 2, high retention of 188Re labeled ca-
tionic polymers in the tumor were not only inspected through
nuclear imaging of good quality because of appropriate gamma
energy for imaging, but also predicted extensive necrosis
around the sites of injection. We verified that injected and
retained dose, 11.1 MBq, of 188Re HYNIC-PEI-Tf was en-
ough to cause the necrosis to approximately 1cm-sized tumor
through calculated results for dosimetry using the Nodule
Module in MIRDOSE3.1 software.
In conclusion, the results of this preliminary study show
that 188Re labeled HYNIC-PEI-Tf can be a useful radiophar-
maceutical agent to treat solid tumors when delivered by
intratumoral injection.
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